CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for PolyMedix, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

PolyMedix, Inc.
170 N Radnor Chester Rd Ste 300
Phone: (484) 598-2370p:484 598-2370 WAYNE, PA  19087-5279  United States Ticker: PYMX PYMX
On 9/9/2013, substantially all of the Company's assets were acquired by Cellceutix Corp.
This company is no longer actively traded on any major stock exchange.
Business Summary
PolyMedix, Inc. (PolyMedix) is a clinical-stage biotechnology company. PolyMedix is engaged in developing small-molecule drugs for the treatment of serious acute care conditions. The Company has created defensin mimetic antibiotic compounds, heparin antagonist compounds, and other drug compounds intended for human therapeutic. The Company has internally created a pipeline of infectious disease, cancer supportive care and cardiovascular product candidates. The Company’s product includes PMX-30063 and PMX-60056 and other PMX defensin-mimetics. In February 2011, the Company completed and announced positive results from a randomized, double-blind, placebo-controlled Phase I exposure-escalation clinical study where it evaluated the safety and pharmacokinetics of PMX-30063 in once-daily dosing up to 14 days.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/201212/31/2011YesYesYes--

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Shaun F.O'Malley 76 6/17/2011 1/1/2006
Chief Medical Officer, Senior Vice President - Clinical Development DanielJorgensen 8/1/2011 8/1/2011
Vice President - Drug Development BozenaKorczak 59 12/1/2011 11/12/2007
4 additional Officers and Directors records available in full report.

Business Names
Business Name
PolyMedix Pharmaceuticals, Inc.
PYMX

General Information
Number of Employees: 28 (As of 12/31/2011)
Outstanding Shares: 2,135,826 (As of 3/19/2013)
Shareholders: 700
Stock Exchange: OTC
Federal Tax Id: 270125925
Fax Number: (484) 598-2401


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023